PDE5 Inhibition Via Tadalafil (Cialis) to Enhance Anti-Tumor MUC1 Vaccine Efficacy in Patients With Resectable, and Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase I/II Clinical Trial
Phase of Trial: Phase I/II
Latest Information Update: 14 Mar 2017
At a glance
- Drugs Tadalafil (Primary) ; Cancer vaccine MUC-1; Influenza virus vaccine
- Indications Head and neck cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Apr 2016 Treatment arms changed from 4 to 5.
- 08 Apr 2016 Planned primary completion date changed from 1 Dec 2020 to 1 Apr 2021.
- 08 Apr 2016 Planned number of patients changed from 54 to 104.